Compare IVR & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVR | AUTL |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.0M | 596.2M |
| IPO Year | 2008 | 2025 |
| Metric | IVR | AUTL |
|---|---|---|
| Price | $5.69 | $1.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $8.17 | ★ $8.73 |
| AVG Volume (30 Days) | ★ 3.3M | 1.4M |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | ★ 25.35% | N/A |
| EPS Growth | ★ 103.08 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $88.36 | $98.68 |
| Revenue Next Year | $8.03 | $28.47 |
| P/E Ratio | $56.80 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $5.52 | $1.18 |
| 52 Week High | $9.50 | $2.58 |
| Indicator | IVR | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 20.31 | 41.14 |
| Support Level | N/A | $1.37 |
| Resistance Level | $8.24 | $1.92 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 14.54 | 22.22 |
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.